{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:50:57Z","timestamp":1791366657386,"version":"4.3.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"41","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA298993"],"award-info":[{"award-number":["CA298993"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["22CHAL13"],"award-info":[{"award-number":["22CHAL13"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005440","name":"U.S. Department of Health & Human Services | NIH | Center for Scientific Review","doi-asserted-by":"publisher","award":["CA234162"],"award-info":[{"award-number":["CA234162"]}],"id":[{"id":"10.13039\/100005440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,10,28]]},"DOI":"10.1038\/s41388-026-03969-5","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:03:03Z","timestamp":1788213783000},"page":"4442-4453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuromedin U \u2018innervation\u2019 reprograms myeloid immunosuppression in neuroendocrine prostate cancer"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5671-928X","authenticated-orcid":false,"given":"Michela","family":"Perego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"Madzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew V.","family":"Kossenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Cansu","family":"Atilgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Tazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Tumedei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Limarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Lolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Gurioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3945-8513","authenticated-orcid":false,"given":"Alessandro","family":"Fatatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary V.","family":"Iacocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9109-3294","authenticated-orcid":false,"given":"Justine J.","family":"Jacobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1021-1827","authenticated-orcid":false,"given":"David W.","family":"Goodrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia R.","family":"Languino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-3469","authenticated-orcid":false,"given":"Dario C.","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"3969_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cell.2020.03.034","volume":"181","author":"M Monje","year":"2020","unstructured":"Monje M, Borniger JC, D\u2019Silva NJ, Deneen B, Dirks PB, Fattahi F, et al. Roadmap for the emerging field of cancer neuroscience. Cell. 2020;181:219\u201322.","journal-title":"Cell"},{"key":"3969_CR2","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S1470-2045(21)00596-9","volume":"23","author":"DD Shi","year":"2022","unstructured":"Shi DD, Guo JA, Hoffman HI, Su J, Mino-Kenudson M, Barth JL, et al. Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. Lancet Oncol. 2022;23:e62\u2013e74.","journal-title":"Lancet Oncol"},{"key":"3969_CR3","doi-asserted-by":"publisher","first-page":"7593","DOI":"10.1158\/1078-0432.CCR-08-1164","volume":"14","author":"GE Ayala","year":"2008","unstructured":"Ayala GE, Dai H, Powell M, Li R, Ding Y, Wheeler TM, et al. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008;14:7593\u2013603.","journal-title":"Clin Cancer Res"},{"key":"3969_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1126\/science.aah5072","volume":"358","author":"AH Zahalka","year":"2017","unstructured":"Zahalka AH, Arnal-Estape A, Maryanovich M, Nakahara F, Cruz CD, Finley LWS, et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science. 2017;358:321\u20136.","journal-title":"Science"},{"key":"3969_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41585-019-0274-3","volume":"17","author":"B March","year":"2020","unstructured":"March B, Faulkner S, Jobling P, Steigler A, Blatt A, Denham J, et al. Tumour innervation and neurosignalling in prostate cancer. Nat Rev Urol. 2020;17:119\u201330.","journal-title":"Nat Rev Urol"},{"key":"3969_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/science.1236361","volume":"341","author":"C Magnon","year":"2013","unstructured":"Magnon C, Hall SJ, Lin J, Xue X, Gerber L, Freedland SJ, et al. Autonomic nerve development contributes to prostate cancer progression. Science. 2013;341:1236361.","journal-title":"Science"},{"key":"3969_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13578-023-01008-4","volume":"13","author":"M Di Donato","year":"2023","unstructured":"Di Donato M, Giovannelli P, Migliaccio A, Castoria G. The nerve growth factor-delivered signals in prostate cancer and its associated microenvironment: when the dialogue replaces the monologue. Cell Biosci. 2023;13:60.","journal-title":"Cell Biosci"},{"key":"3969_CR8","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","volume":"39","author":"Y Kfoury","year":"2021","unstructured":"Kfoury Y, Baryawno N, Severe N, Mei S, Gustafsson K, Hirz T, et al. Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell. 2021;39:1464\u201378.e1468.","journal-title":"Cancer Cell"},{"key":"3969_CR9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.tem.2024.12.003","volume":"36","author":"L Brea","year":"2025","unstructured":"Brea L, Yu J. Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer. Trends Endocrinol Metab. 2025;36:855\u201366.","journal-title":"Trends Endocrinol Metab"},{"key":"3969_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/pros.23454","volume":"78","author":"C Coarfa","year":"2018","unstructured":"Coarfa C, Florentin D, Putluri N, Ding Y, Au J, He D, et al. Influence of the neural microenvironment on prostate cancer. Prostate. 2018;78:128\u201339.","journal-title":"Prostate"},{"key":"3969_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2025.152425","volume":"53","author":"D Sigorski","year":"2026","unstructured":"Sigorski D, Kasprzyk-Pawelec A, Michalak M, Sosnowski R, Hryciuk MM, Sejda A, et al. The nervous system in prostate cancer: a basic science and clinical perspective. Semin Oncol. 2026;53:152425.","journal-title":"Semin Oncol"},{"key":"3969_CR12","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492\u2013503.","journal-title":"J Clin Oncol"},{"key":"3969_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","volume":"32","author":"EG Bluemn","year":"2017","unstructured":"Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474\u201389.e476.","journal-title":"Cancer Cell"},{"key":"3969_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"3969_CR15","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1158\/2159-8290.CD-16-1174","volume":"7","author":"M Zou","year":"2017","unstructured":"Zou M, Toivanen R, Mitrofanova A, Floch N, Hayati S, Sun Y, et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov. 2017;7:736\u201349.","journal-title":"Cancer Discov"},{"key":"3969_CR16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell. 2016;30:563\u201377.","journal-title":"Cancer Cell"},{"key":"3969_CR17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","volume":"29","author":"JK Lee","year":"2016","unstructured":"Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, et al. N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells. Cancer Cell. 2016;29:536\u201347.","journal-title":"Cancer Cell"},{"key":"3969_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aat5749","volume":"362","author":"JW Park","year":"2018","unstructured":"Park JW, Lee JK, Sheu KM, Wang L, Balanis NG, Nguyen K, et al. Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science. 2018;362:91\u201395.","journal-title":"Science"},{"key":"3969_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06067-7","volume":"9","author":"Q Li","year":"2018","unstructured":"Li Q, Deng Q, Chao HP, Liu X, Lu Y, Lin K, et al. Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun. 2018;9:3600.","journal-title":"Nat Commun"},{"key":"3969_CR20","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","volume":"32","author":"HT Wang","year":"2014","unstructured":"Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol. 2014;32:3383\u201390.","journal-title":"J Clin Oncol"},{"key":"3969_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218070","volume":"634","author":"F Vanden Abeele","year":"2025","unstructured":"Vanden Abeele F, Salzet M. The neuro-immune oncology axis. Cancer Lett. 2025;634:218070.","journal-title":"Cancer Lett"},{"key":"3969_CR22","doi-asserted-by":"crossref","unstructured":"Liu Z, Peng Q, Wang Y, Chiu PK, Teoh JY, Wang R, et al. Neuroscience in prostate cancer. Prostate Cancer Prostatic Dis. 2026;29:478\u201387.","DOI":"10.1038\/s41391-025-01042-y"},{"key":"3969_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nature24014","volume":"549","author":"HS Venkatesh","year":"2017","unstructured":"Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 2017;549:533\u20137.","journal-title":"Nature"},{"key":"3969_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2026.1667459","volume":"14","author":"N Aysit","year":"2026","unstructured":"Aysit N, Altintas E, Koksalar Alkan F, Ozturk G, Korkaya H. The neural niche in cancer: mechanistic insights into tumor-neuron-immune crosstalk and therapeutic opportunities. Front Cell Dev Biol. 2026;14:1667459.","journal-title":"Front Cell Dev Biol"},{"key":"3969_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/1078-0432.CCR-20-2381","volume":"27","author":"S Gandhi","year":"2021","unstructured":"Gandhi S, Pandey MR, Attwood K, Ji W, Witkiewicz AK, Knudsen ES, et al. Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity. Clin Cancer Res. 2021;27:87\u201395.","journal-title":"Clin Cancer Res"},{"key":"3969_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nature23676","volume":"549","author":"CSN Klose","year":"2017","unstructured":"Klose CSN, Mahlakoiv T, Moeller JB, Rankin LC, Flamar AL, Kabata H, et al. The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation. Nature. 2017;549:282\u20136.","journal-title":"Nature"},{"key":"3969_CR27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1126\/science.ade4177","volume":"381","author":"Y Li","year":"2023","unstructured":"Li Y, Liu S, Zhou K, Wang Y, Chen Y, Hu W, et al. Neuromedin U programs eosinophils to promote mucosal immunity of the small intestine. Science. 2023;381:1189\u201396.","journal-title":"Science"},{"key":"3969_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1084\/jem.20050248","volume":"202","author":"M Moriyama","year":"2005","unstructured":"Moriyama M, Sato T, Inoue H, Fukuyama S, Teranishi H, Kangawa K, et al. The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells. J Exp Med. 2005;202:217\u201324.","journal-title":"J Exp Med"},{"key":"3969_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1373\/clinchem.2014.231753","volume":"61","author":"VG Martinez","year":"2015","unstructured":"Martinez VG, O\u2019Driscoll L. Neuromedin U: a multifunctional neuropeptide with pleiotropic roles. Clin Chem. 2015;61:471\u201382.","journal-title":"Clin Chem"},{"key":"3969_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1177\/15578100261422815","volume":"30","author":"L Dcunha","year":"2026","unstructured":"Dcunha L, Edakkad B, Fathima I, Dagamajalu S, Raju R, Devasahayam Arokia Balaya R, et al. Neuromedin U signaling map: toward neuropeptide focused therapeutic targets in cancer and human diseases. OMICS. 2026;30:211\u201323.","journal-title":"OMICS"},{"key":"3969_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.713961","volume":"12","author":"LK Malendowicz","year":"2021","unstructured":"Malendowicz LK, Rucinski M. Neuromedins NMU and NMS: an updated overview of their functions. Front Endocrinol. 2021;12:713961.","journal-title":"Front Endocrinol"},{"key":"3969_CR32","doi-asserted-by":"publisher","first-page":"32452","DOI":"10.1074\/jbc.M004613200","volume":"275","author":"R Raddatz","year":"2000","unstructured":"Raddatz R, Wilson AE, Artymyshyn R, Bonini JA, Borowsky B, Boteju LW, et al. Identification and characterization of two neuromedin U receptors differentially expressed in peripheral tissues and the central nervous system. J Biol Chem. 2000;275:32452\u20139.","journal-title":"J Biol Chem"},{"key":"3969_CR33","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/cancers11091312","volume":"11","author":"P Przygodzka","year":"2019","unstructured":"Przygodzka P, Soboska K, Sochacka E, Boncela J. Neuromedin U: a small peptide in the big world of cancer. Cancers. 2019;11:1312.","journal-title":"Cancers"},{"key":"3969_CR34","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3390\/cancers16101875","volume":"16","author":"D Benzaquen","year":"2024","unstructured":"Benzaquen D, Lawrence YR, Taussky D, Zwahlen D, Oehler C, Champion A. The crosstalk between nerves and cancer-A poorly understood phenomenon and new possibilities. Cancers. 2024;16:1875.","journal-title":"Cancers"},{"key":"3969_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189269","volume":"1880","author":"P Przygodzka","year":"2025","unstructured":"Przygodzka P, Szulc-Kielbik I, Kielbik M, Pacholczyk M, Klink M. Neuromedin U in the tumor microenvironment - Possible actions in tumor progression. Biochim Biophys Acta Rev Cancer. 2025;1880:189269.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3969_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"3969_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinforma. 2011;12:323.","journal-title":"BMC Bioinforma"},{"key":"3969_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"3969_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0192623311425062","volume":"40","author":"LD Berman-Booty","year":"2012","unstructured":"Berman-Booty LD, Sargeant AM, Rosol TJ, Rengel RC, Clinton SK, Chen CS, et al. A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice. Toxicol Pathol. 2012;40:5\u201317.","journal-title":"Toxicol Pathol"},{"key":"3969_CR40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322203121","volume":"121","author":"S Zaidi","year":"2024","unstructured":"Zaidi S, Park J, Chan JM, Roudier MP, Zhao JL, Gopalan A, et al. Single cell analysis of treatment-resistant prostate cancer: implications of cell state changes for cell surface antigen targeted therapies. Proc Natl Acad Sci USA. 2024;121:e2322203121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3969_CR41","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, Coleman IM, Brown LG, True LD, Kollath L, Lakely B, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019;129:4492\u2013505.","journal-title":"J Clin Invest"},{"key":"3969_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-026-16127-7","volume":"26","author":"Q Zheng","year":"2026","unstructured":"Zheng Q, Xie X, Guo Q, Chen C, Jiang W. Prognostic value of tumor-infiltrating lymphocytes and common subtypes in patients with gastroenteropancreatic neuroendocrine neoplasms: a systematic review and meta-analysis. BMC Cancer. 2026;26:793.","journal-title":"BMC Cancer"},{"key":"3969_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cllc.2026.01.003","volume":"27","author":"AML Yeung","year":"2026","unstructured":"Yeung AML, Chow JCH. Management of pulmonary large-cell neuroendocrine carcinoma (LCNEC): an updated review. Clin Lung Cancer. 2026;27:85\u201397.","journal-title":"Clin Lung Cancer"},{"key":"3969_CR44","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1056\/NEJMcibr1714003","volume":"378","author":"D Chen","year":"2018","unstructured":"Chen D, Ayala GE. Innervating prostate cancer. N Engl J Med. 2018;378:675\u20137.","journal-title":"N Engl J Med"},{"key":"3969_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-030-35723-8_8","volume":"1224","author":"M Dysthe","year":"2020","unstructured":"Dysthe M, Parihar R. Myeloid-derived suppressor cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1224:117\u201340.","journal-title":"Adv Exp Med Biol"},{"key":"3969_CR46","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S1470-2045(16)30272-8","volume":"17","author":"V Brower","year":"2016","unstructured":"Brower V. Tasquinimod treatment for prostate cancer. Lancet Oncol. 2016;17:e322.","journal-title":"Lancet Oncol"},{"key":"3969_CR47","doi-asserted-by":"publisher","first-page":"L971","DOI":"10.1152\/ajplung.00345.2005","volume":"290","author":"M Moriyama","year":"2006","unstructured":"Moriyama M, Fukuyama S, Inoue H, Matsumoto T, Sato T, Tanaka K, et al. The neuropeptide neuromedin U activates eosinophils and is involved in allergen-induced eosinophilia. Am J Physiol Lung Cell Mol Physiol. 2006;290:L971\u2013977.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"3969_CR48","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162\u201374.","journal-title":"Nat Rev Immunol"},{"key":"3969_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-01003-1","volume":"20","author":"P Przygodzka","year":"2022","unstructured":"Przygodzka P, Soboska K, Sochacka E, Pacholczyk M, Braun M, Kassassir H, et al. Neuromedin U secreted by colorectal cancer cells promotes a tumour-supporting microenvironment. Cell Commun Signal. 2022;20:193.","journal-title":"Cell Commun Signal"},{"key":"3969_CR50","doi-asserted-by":"publisher","first-page":"7230","DOI":"10.4049\/jimmunol.173.12.7230","volume":"173","author":"EN Johnson","year":"2004","unstructured":"Johnson EN, Appelbaum ER, Carpenter DC, Cox RF, Disa J, Foley JJ, et al. Neuromedin U elicits cytokine release in murine Th2-type T cell clone D10.G4.1. J Immunol. 2004;173:7230\u20138.","journal-title":"J Immunol"},{"key":"3969_CR51","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/cas.16024","volume":"115","author":"R Zheng","year":"2024","unstructured":"Zheng R, Wang S, Wang J, Zhou M, Shi Q, Liu B. Neuromedin U regulates the anti-tumor activity of CD8(+) T cells and glycolysis of tumor cells in the tumor microenvironment of pancreatic ductal adenocarcinoma in an NMUR1-dependent manner. Cancer Sci. 2024;115:334\u201346.","journal-title":"Cancer Sci"},{"key":"3969_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110318","volume":"27","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhang X, Gao Y, Peng Y, Liu P, Chen Y, et al. Neuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer. iScience. 2024;27:110318.","journal-title":"iScience"},{"key":"3969_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188891","volume":"1878","author":"Y Chen","year":"2023","unstructured":"Chen Y, Ouyang Y, Li Z, Wang X, Ma J. S100A8 and S100A9 in cancer. Biochim Biophys Acta Rev Cancer. 2023;1878:188891.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3969_CR54","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.7150\/thno.17138","volume":"7","author":"M Eisenblaetter","year":"2017","unstructured":"Eisenblaetter M, Flores-Borja F, Lee JJ, Wefers C, Smith H, Hueting R, et al. Visualization of tumor-immune interaction - target-specific imaging of S100A8\/A9 reveals pre-metastatic niche establishment. Theranostics. 2017;7:2392\u2013401.","journal-title":"Theranostics"},{"key":"3969_CR55","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/cells11020236","volume":"11","author":"EGG Sprenkeler","year":"2022","unstructured":"Sprenkeler EGG, Zandstra J, van Kleef ND, Goetschalckx I, Verstegen B, Aarts CEM, et al. S100A8\/A9 is a marker for the release of neutrophil extracellular traps and induces neutrophil activation. Cells. 2022;11:236.","journal-title":"Cells"},{"key":"3969_CR56","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.cell.2020.08.002","volume":"182","author":"A Silvin","year":"2020","unstructured":"Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell. 2020;182:1401\u201318.e1418.","journal-title":"Cell"},{"key":"3969_CR57","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yexcr.2015.04.008","volume":"334","author":"R Wu","year":"2015","unstructured":"Wu R, Duan L, Cui F, Cao J, Xiang Y, Tang Y, et al. S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1\/2 and p38 MAPK pathways. Exp Cell Res. 2015;334:228\u201338.","journal-title":"Exp Cell Res"},{"key":"3969_CR58","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1038\/onc.2016.448","volume":"36","author":"Q Yang","year":"2017","unstructured":"Yang Q, Li X, Chen H, Cao Y, Xiao Q, He Y, et al. IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer. Oncogene. 2017;36:2969\u201380.","journal-title":"Oncogene"},{"key":"3969_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108571","volume":"33","author":"T Kwak","year":"2020","unstructured":"Kwak T, Wang F, Deng H, Condamine T, Kumar V, Perego M, et al. Distinct populations of immune-suppressive macrophages differentiate from monocytic myeloid-derived suppressor cells in cancer. Cell Rep. 2020;33:108571.","journal-title":"Cell Rep"},{"key":"3969_CR60","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fimmu.2017.00358","volume":"8","author":"RLG Maus","year":"2017","unstructured":"Maus RLG, Jakub JW, Nevala WK, Christensen TA, Noble-Orcutt K, Sachs Z, et al. Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front Immunol. 2017;8:358.","journal-title":"Front Immunol"},{"key":"3969_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848367","volume":"13","author":"L Zhou","year":"2022","unstructured":"Zhou L, Wang M, Guo H, Hou J, Zhang Y, Li M, et al. Integrated analysis highlights the immunosuppressive role of TREM2(+) macrophages in hepatocellular carcinoma. Front Immunol. 2022;13:848367.","journal-title":"Front Immunol"},{"key":"3969_CR62","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.immuni.2013.02.007","volume":"38","author":"M Sade-Feldman","year":"2013","unstructured":"Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity. 2013;38:541\u201354.","journal-title":"Immunity"},{"key":"3969_CR63","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1158\/0008-5472.CAN-12-4213","volume":"73","author":"M Ittmann","year":"2013","unstructured":"Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013;73:2718\u201336.","journal-title":"Cancer Res"},{"key":"3969_CR64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2164\/jandrol.111.013987","volume":"33","author":"PJ Hensley","year":"2012","unstructured":"Hensley PJ, Kyprianou N. Modeling prostate cancer in mice: limitations and opportunities. J Androl. 2012;33:133\u201344.","journal-title":"J Androl"},{"key":"3969_CR65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10555-012-9409-1","volume":"32","author":"S Irshad","year":"2013","unstructured":"Irshad S, Abate-Shen C. Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev. 2013;32:109\u201322.","journal-title":"Cancer Metastasis Rev"},{"key":"3969_CR66","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403.","journal-title":"Cancer Cell"},{"key":"3969_CR67","doi-asserted-by":"publisher","first-page":"e31918","DOI":"10.7554\/eLife.31918","volume":"7","author":"K Chia","year":"2018","unstructured":"Chia K, Mazzolini J, Mione M, Sieger D. Tumor initiating cells induce Cxcr4-mediated infiltration of pro-tumoral macrophages into the brain. Elife. 2018;7:e31918.","journal-title":"Elife"},{"key":"3969_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02481-5","volume":"9","author":"N Linde","year":"2018","unstructured":"Linde N, Casanova-Acebes M, Sosa MS, Mortha A, Rahman A, Farias E, et al. Macrophages orchestrate breast cancer early dissemination and metastasis. Nat Commun. 2018;9:21.","journal-title":"Nat Commun"},{"key":"3969_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8802","volume":"6","author":"K Asano","year":"2015","unstructured":"Asano K, Takahashi N, Ushiki M, Monya M, Aihara F, Kuboki E, et al. Intestinal CD169(+) macrophages initiate mucosal inflammation by secreting CCL8 that recruits inflammatory monocytes. Nat Commun. 2015;6:7802.","journal-title":"Nat Commun"},{"key":"3969_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18207-z","volume":"11","author":"Y Schlesinger","year":"2020","unstructured":"Schlesinger Y, Yosefov-Levi O, Kolodkin-Gal D, Granit RZ, Peters L, Kalifa R, et al. Single-cell transcriptomes of pancreatic preinvasive lesions and cancer reveal acinar metaplastic cells\u2019 heterogeneity. Nat Commun. 2020;11:4516.","journal-title":"Nat Commun"},{"key":"3969_CR71","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","volume":"29","author":"B Bhinder","year":"2023","unstructured":"Bhinder B, Ferguson A, Sigouros M, Uppal M, Elsaeed AG, Bareja R, et al. Immunogenomic landscape of neuroendocrine prostate cancer. Clin Cancer Res. 2023;29:2933\u201343.","journal-title":"Clin Cancer Res"},{"key":"3969_CR72","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/s43018-024-00838-6","volume":"5","author":"R Romero","year":"2024","unstructured":"Romero R, Chu T, Gonzalez Robles TJ, Smith P, Xie Y, Kaur H, et al. The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. Nat Cancer. 2024;5:1641\u201359.","journal-title":"Nat Cancer"},{"key":"3969_CR73","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/PPO.0000000000000176","volume":"22","author":"S Goswami","year":"2016","unstructured":"Goswami S, Aparicio A, Subudhi SK. Immune checkpoint therapies in prostate cancer. Cancer J. 2016;22:117\u201320.","journal-title":"Cancer J"},{"key":"3969_CR74","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","volume":"559","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018;559:363\u20139.","journal-title":"Nature"},{"key":"3969_CR75","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2326-6066.CIR-17-0385","volume":"6","author":"E Jachetti","year":"2018","unstructured":"Jachetti E, Cancila V, Rigoni A, Bongiovanni L, Cappetti B, Belmonte B, et al. Cross-talk between myeloid-derived suppressor cells and mast cells mediates tumor-specific immunosuppression in prostate cancer. Cancer Immunol Res. 2018;6:552\u201365.","journal-title":"Cancer Immunol Res"},{"key":"3969_CR76","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","volume":"623","author":"C Guo","year":"2023","unstructured":"Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, et al. Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. Nature. 2023;623:1053\u201361.","journal-title":"Nature"},{"key":"3969_CR77","first-page":"1832","volume":"62","author":"RS Taichman","year":"2002","unstructured":"Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1\/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832\u20137.","journal-title":"Cancer Res"},{"key":"3969_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1626708","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Zhang L, Liu R, Xu C, Tang H, Zou Y, et al. CXCL12\/CXCR4 axis governs Treg spatial dominance over CD8+ T cells via IL-2 sequestration: a dual therapeutic target in prostate cancer. Front Immunol. 2025;16:1626708.","journal-title":"Front Immunol"},{"key":"3969_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-013-2321-8","volume":"73","author":"E Raymond","year":"2014","unstructured":"Raymond E, Dalgleish A, Damber JE, Smith M, Pili R. Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharm. 2014;73:1\u20138.","journal-title":"Cancer Chemother Pharm"},{"key":"3969_CR80","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui I, Schaeuble K, Chennupati V, Fuertes Marraco SA, Calderon-Copete S, Pais Ferreira D, et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019;50:195\u2013211.e110.","journal-title":"Immunity"},{"key":"3969_CR81","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/cdd.2009.206","volume":"17","author":"SP Cullen","year":"2010","unstructured":"Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ. 2010;17:616\u201323.","journal-title":"Cell Death Differ"},{"key":"3969_CR82","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20:326\u201336.","journal-title":"Nat Immunol"},{"key":"3969_CR83","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1200\/JCO.2011.35.6295","volume":"29","author":"R Pili","year":"2011","unstructured":"Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Bjork A, et al. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011;29:4022\u20138.","journal-title":"J Clin Oncol"},{"key":"3969_CR84","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","volume":"34","author":"C Sternberg","year":"2016","unstructured":"Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, et al. Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer. J Clin Oncol. 2016;34:2636\u201343.","journal-title":"J Clin Oncol"},{"key":"3969_CR85","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025;637:1207\u201317.","journal-title":"Nature"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03969-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03969-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03969-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:03:33Z","timestamp":1791363813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03969-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":85,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2026,10,28]]}},"alternative-id":["3969"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03969-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}